In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Wins OSI But Victory Comes At A Price

Executive Summary

Japanese drugmaker Astellas Pharma's painstaking pursuit of OSI Pharmaceuticals is officially over. The victory came at a price, however, costing $4 billion, about $500 million more than Astellas' original hostile bid, launched in late February. That Astellas and OSI managed to find a path forward isn't surprising. Both companies had too much at stake not to see the merger come to fruition.
Advertisement

Related Content

Astellas U.S. Priorities Are Oncology Expansion, BD – President Robinson
Broader Indications For Tarceva As Astellas Scales Back In The U.S.
The Rise Of Japanese Pharma Dealmakers
The Rise Of Japanese Pharma Dealmakers
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures
Takeda's Global Ambition
Takeda's Global Ambition
Takeda/ Millennium: The Price is Right

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel